159 , 160 The effect of zoledronic acid on overall survival was reported to be independent of the reduction in SREs, suggesting more direct anti‐myeloma effects, 159 , 160 although a subsequent analysis of the data suggested this effect did not quite reach statistical significance ( p = .0515). 161 A meta‐analysis of eight randomised studies involving patients with early stage breast cancer suggested that adjuvant bisphosphonate use was associated with a reduction in the rate of breast cancer recurrence in the bone (relative risk 0.83, p = .004) and modest reduction in b
← all excerpts
Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.
1
0.0515
0.0515